Do analysts rate TNON or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate NVNO or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NVNO or VBIO?

enVVeno Medical is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$25.54 N/A Valion Bio, Inc. Common Stock N/A N/A -$8.88M -$6.68 N/A

Is NVNO or VBIO more profitable?

enVVeno Medical's return on equity of -66.39% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -66.39% -60.42% Valion Bio, Inc. Common Stock N/A -138.10% -63.67%

Do analysts rate VBIO or HSCS?

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 344.44%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, VBIO or HSCS?

HeartSciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valion Bio, Inc. Common Stock N/A N/A -$8.88M -$6.68 N/A HeartSciences N/A N/A -$8.77M -$4.94 N/A

Is VBIO or HSCS more profitable?

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -138.10% -63.67% HeartSciences N/A -333.50% -140.18%

Do analysts recommend VBIO or LUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend NDRA or VBIO?

ENDRA Life Sciences currently has a consensus price target of $25.00, indicating a potential upside of 448.25%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, NDRA or VBIO?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A Valion Bio, Inc. Common Stock N/A N/A -$8.88M -$6.68 N/A

Is NDRA or VBIO more profitable?

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -433.64% -204.58% Valion Bio, Inc. Common Stock N/A -138.10% -63.67%

Valion Bio, Inc. Common Stock (VBIO) Competitors

$0.57 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

VBIO vs. TNON, NVNO, HSCS, LUCY, and NDRA

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? MarketBeat compares Valion Bio, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valion Bio, Inc. Common Stock include Tenon Medical (TNON), enVVeno Medical (NVNO), HeartSciences (HSCS), Innovative Eyewear (LUCY), and ENDRA Life Sciences (NDRA). These companies are all part of the "medical equipment" industry.

How does Valion Bio, Inc. Common Stock compare to Tenon Medical?

Tenon Medical (NASDAQ:TNON) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Tenon Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Tenon Medical's net margin of -270.09%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Tenon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenon Medical	-270.09%	-907.60%	-110.17%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.7% of Tenon Medical shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 0.3% of Tenon Medical shares are held by company insiders. Comparatively, 14.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Tenon Medical had 2 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 3 mentions for Tenon Medical and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.87 beat Tenon Medical's score of 1.51 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Tenon Medical	Very Positive
Valion Bio, Inc. Common Stock	Very Positive

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Tenon Medical. Tenon Medical is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenon Medical	$4.60M	1.55	-$12.56M	-$1.29	N/A
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A

Summary

Valion Bio, Inc. Common Stock beats Tenon Medical on 8 of the 14 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

enVVeno Medical has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

In the previous week, enVVeno Medical and enVVeno Medical both had 1 articles in the media. enVVeno Medical's average media sentiment score of 1.87 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

Company	Overall Sentiment
enVVeno Medical	Very Positive
Valion Bio, Inc. Common Stock	Very Positive

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by company insiders. Comparatively, 14.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

enVVeno Medical is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A

enVVeno Medical's return on equity of -66.39% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-66.39%	-60.42%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

enVVeno Medical beats Valion Bio, Inc. Common Stock on 5 of the 9 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to HeartSciences?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 344.44%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HeartSciences had 3 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 4 mentions for HeartSciences and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.87 beat HeartSciences' score of 0.75 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Very Positive
HeartSciences	Positive

HeartSciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A
HeartSciences	N/A	N/A	-$8.77M	-$4.94	N/A

Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
HeartSciences	N/A	-333.50%	-140.18%

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

HeartSciences beats Valion Bio, Inc. Common Stock on 8 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Innovative Eyewear?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Innovative Eyewear had 1 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 2 mentions for Innovative Eyewear and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.87 beat Innovative Eyewear's score of 1.45 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Very Positive
Innovative Eyewear	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Innovative Eyewear has higher revenue and earnings than Valion Bio, Inc. Common Stock. Innovative Eyewear is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A
Innovative Eyewear	$2.66M	2.09	-$7.59M	-$1.69	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Innovative Eyewear	-272.42%	-83.37%	-76.02%

Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market.

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Innovative Eyewear beats Valion Bio, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 14.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 2 mentions for ENDRA Life Sciences and 1 mentions for Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock's average media sentiment score of 1.87 beat ENDRA Life Sciences' score of 1.43 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
ENDRA Life Sciences	Positive
Valion Bio, Inc. Common Stock	Very Positive

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A

ENDRA Life Sciences currently has a consensus price target of $25.00, indicating a potential upside of 448.25%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Valion Bio, Inc. Common Stock's return on equity of -138.10% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

ENDRA Life Sciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Summary

Valion Bio, Inc. Common Stock beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.81M	$1.50B	$6.52B	$12.05B
Dividend Yield	N/A	N/A	2.67%	5.66%
P/E Ratio	-0.08	77.55	24.00	24.42
Price / Sales	N/A	6.92	515.84	118.72
Price / Cash	N/A	22.98	27.48	37.92
Price / Book	0.09	4.82	10.60	6.82
Net Income	-$8.88M	-$54.76M	$3.57B	$337.56M
7 Day Performance	-26.01%	-1.67%	0.59%	1.16%
1 Month Performance	-35.68%	0.13%	1.54%	3.16%
1 Year Performance	-84.74%	-6.47%	25.41%	30.60%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	2.1081 of 5 stars	$0.57 flat	N/A	-84.7%	$1.81M	N/A	N/A	10	Positive News Gap Up
TNON Tenon Medical	1.3898 of 5 stars	$0.63 +0.7%	N/A	-29.9%	$7.29M	$4.60M	N/A	8
NVNO enVVeno Medical	0.8721 of 5 stars	$10.71 -0.4%	N/A	-93.4%	$7.18M	N/A	N/A	30
HSCS HeartSciences	2.7923 of 5 stars	$2.04 -1.4%	$8.00 +292.2%	-49.6%	$6.50M	$8.67K	N/A	10
LUCY Innovative Eyewear	1.5786 of 5 stars	$0.96 +1.1%	N/A	-64.5%	$6.15M	$2.98M	N/A	9	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. TNON, NVNO, HSCS, LUCY, and NDRA

How does Valion Bio, Inc. Common Stock compare to Tenon Medical?

Summary

How does Valion Bio, Inc. Common Stock compare to enVVeno Medical?

Summary

How does Valion Bio, Inc. Common Stock compare to HeartSciences?

Summary

How does Valion Bio, Inc. Common Stock compare to Innovative Eyewear?

Summary

How does Valion Bio, Inc. Common Stock compare to ENDRA Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. TNON, NVNO, HSCS, LUCY, and NDRA

How does Valion Bio, Inc. Common Stock compare to Tenon Medical?

Which has more volatility and risk, TNON or VBIO?

Is TNON or VBIO more profitable?

Do analysts rate TNON or VBIO?

Do insiders and institutionals have more ownership in TNON or VBIO?

Does the media refer more to TNON or VBIO?

Which has higher earnings and valuation, TNON or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to enVVeno Medical?

Which has more risk & volatility, NVNO or VBIO?

Does the media favor NVNO or VBIO?

Do institutionals & insiders hold more shares of NVNO or VBIO?

Which has better valuation and earnings, NVNO or VBIO?

Is NVNO or VBIO more profitable?

Do analysts rate NVNO or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to HeartSciences?

Do analysts rate VBIO or HSCS?

Does the media prefer VBIO or HSCS?

Which has higher valuation & earnings, VBIO or HSCS?

Which has more volatility and risk, VBIO or HSCS?

Is VBIO or HSCS more profitable?

Do institutionals & insiders hold more shares of VBIO or HSCS?

Summary

How does Valion Bio, Inc. Common Stock compare to Innovative Eyewear?

Does the media refer more to VBIO or LUCY?

Do analysts recommend VBIO or LUCY?

Which has stronger earnings and valuation, VBIO or LUCY?

Is VBIO or LUCY more profitable?

Which has more risk & volatility, VBIO or LUCY?

Do institutionals and insiders believe in VBIO or LUCY?

Summary

How does Valion Bio, Inc. Common Stock compare to ENDRA Life Sciences?

Do insiders and institutionals believe in NDRA or VBIO?

Does the media favor NDRA or VBIO?

Which has preferable earnings & valuation, NDRA or VBIO?

Do analysts recommend NDRA or VBIO?

Is NDRA or VBIO more profitable?

Which has more volatility & risk, NDRA or VBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools